A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs

Journal of Oncology Practice

Volumn 13, Issue 2, 2017, Pages e108-e119

  Haslem, Derrick S ^a   Van Norman, S Burke ^b   Fulde, Gail ^c   Knighton, Andrew J ^d   Belnap, Tom ^a   Butler, Allison M ^a   Rhagunath, Sharanya ^a   Newman, David ^a   Gilbert, Heather ^a   Tudor, Brian P ^a   Lin, Karen ^a   Stone, Gary R ^a   Loughmiller, David L ^a   Mishra, Pravin J ^a   Srivastava, Rajendu ^a   Ford, James M ^a   Nadauld, Lincoln D ^a  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HISTOLOGY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MALE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; GENETICS; MIDDLE AGED; MOLECULAR DIAGNOSIS; MORTALITY; MUTATION; NEOPLASM;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS; PRECISION MEDICINE; RETROSPECTIVE STUDIES;

EID: 85016800496     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.011486     Document Type: Article

References (27)

1. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative high-Throughput sequencing: A pilot study. Sci Transl Med 3:111ra121, 2011.
2. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014.
3. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012.
4. Fraumeni JF Jr: Constitutional disorders of man predisposing to leukemia and lymphoma. Natl Cancer Inst Monogr 32:221-232, 1969.
5. Garraway LA, Verweij J, Ballman KV: Precision oncology: An overview. J Clin Oncol 31:1803-1805, 2013.
6. Nadauld LD, Ford JM: Molecular profiling of gastric cancer: Toward personalized cancer medicine. J Clin Oncol 31:838-839, 2013.
7. Forbes SA, Bindal N, Bamford S, et al: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-D950, 2011.
8. Margulies M, Egholm M, Altman WE, et al: Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380, 2005.
9. Bentley DR, Balasubramanian S, Swerdlow HP, et al: Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53-59, 2008.
10. Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72, 2008.
11. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001.
12. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000.
13. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002.
14. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
15. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
16. Tommasi S, Paradiso A, Mangia A, et al: Biological correlation between HER-2/neu and proliferative ctivity in human breast cancer. Anticancer Res 11:1395-1400, 1991.
17. Rubin MA: Health: Make precision medicine work for cancer care. Nature 520: 290-291, 2015.
18. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
19. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
20. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
21. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-263, 2012.
22. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005.
23. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014.
24. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 18:6373-6383, 2012.
25. Borad MJ, Champion MD, Egan JB, et al: Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. Plos Genet 10:e1004135, 2014.
26. Liao RG, Jung J, Tchaicha J, et al: Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 73:5195-5205, 2013.
27. Conley AP, Koplin S, Caracciollo JT, et al: Dramatic response to pazopanib in a patientwithmetastaticmalignant granular cell tumor. J Clin Oncol 32:e107-e110, 2014.